Previous 10 | Next 10 |
2023-09-20 17:12:25 ET Gainers: Marinus Pharmaceuticals ( NASDAQ: MRNS ) +8% . Complete Solaria ( CSLR ) +5% . Arhaus ( ARHS ) +5% . COMPASS Pathways ( CMPS ) +5% . Quantum-Si ( QSI ) +5% . Losers: Vahanna Tech ...
2023-09-20 09:30:02 ET More on Relmada Seeking Alpha’s Quant Rating on Relmada Therapeutics Historical earnings data for Relmada Therapeutics Financial information for Relmada Therapeutics Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhan...
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder PR Newswire Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvemen...
2023-09-01 18:53:42 ET Summary Relmada Therapeutics has provided updates on its phase 3 program of esmethadone (REL-1017) as an adjunct in major depressive disorder. An interim analysis could result in an early stoppage, it isn't a guarantee but could enhance the run up effect as ...
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire CORAL GABLES, Fla. , Aug. 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage...
2023-08-11 10:14:56 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . Semler Scientific ( SMLR ) +20% . ModivCare ( MODV ) +15% . Erasca ( ERAS ) +9% . Relmada Therapeutics ( RLMD ) +8% . Losers: Cano Health ( CANO ) -...
2023-08-08 21:46:11 ET Relmada Therapeutics, Inc. (RLMD) Q2 2023 Earnings Conference Call August 08, 2023, 04:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO Cedric O'Gorman - Chief Medical Officer Maged Shenouda - CFO ...
2023-08-08 16:44:44 ET Relmada Therapeutics press release ( NASDAQ: RLMD ): Q2 GAAP EPS of -$0.84 beats by $0.06 . As of June 30, 2023, the Company had cash, cash equivalents, and short-term investments of approximately $118.5 million, compared to cash, cash equivalent...
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results PR Newswire CORAL GABLES, Fla. , Aug. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the...
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 PR Newswire CORAL GABLES, Fla. , Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company...
News, Short Squeeze, Breakout and More Instantly...
Relmada Therapeutics Inc. Company Name:
RLMD Stock Symbol:
OTCMKTS Market:
Relmada Therapeutics Inc. Website:
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry PR Newswire CORAL GABLES, Fla. , June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage b...
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 10, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of t...
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 3, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the cent...